Simultaneous treatment of asthma and allergic rhinitis

Authors

  • Paulo A.M. Camargos MD, PhD,

    Corresponding author
    1. Department of Pediatrics, Medical School and University Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil
    • Department of Pediatrics, Medical School, Federal University of Minas Gerais, Avenida Alfredo Balena, 190/Room 4061, 30130-100 Belo Horizonte, Brazil.
    Search for more papers by this author
  • Mary E.S.M. Rodrigues MD, PhD,

    1. Department of Pediatrics, Medical School and University Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil
    Search for more papers by this author
  • Laura M.L.B.F. Lasmar MD, MSc

    1. Campos Salles Pediatric Pulmonology Outpatient Clinic, Municipal Health Authority, Belo Horizonte, Brazil
    Search for more papers by this author

Abstract

Asthma and allergic rhinitis (AR) form a well-recognized comorbidity. This study aims at assessing the efficacy of nasally inhaled beclomethasone dipropionate (BDP) in their simultaneous treatment. A randomized controlled trial was conducted with 78 allergic rhinitis and asthma patients aged 5–17 years. Seventy-five individuals completed the study. During 8 weeks, 38 subjects received BDP-CFC aerosol (≥ 500 mcg/day) exclusively via nasal inhalation through a facemask attached to a plastic valved spacer. The control group (37 patients) received 200 mcg/day of aqueous intranasal beclomethasone plus oral inhalation of BDP-CFC (≥ 500 mcg/day) through a mouthpiece connected to the same spacer. Primary outcomes analyzed in order to assess the response to treatment were clinical scoring for allergic rhinitis and measurements of nasal inspiratory peak flow (NIPF). AR clinical scoring and NIPF did not differ in the two groups at admission or at nearly all follow-up visits. Nasal inhalation of beclomethasone dipropionate provides AR symptom relief while maintaining control of asthma by delivering it to the lungs. Therefore, this therapeutic strategy might be considered for patients suffering from this comorbidity, especially in low-resource countries, since it is less expensive than the conventional treatment. © 2004 Wiley-Liss, Inc.

Ancillary